Cabaletta Bio, Inc. (CABA): Insider Trading, Congress Trades & Research | Tormere

CABA

$1.30+1.56%visit website

Cabaletta Bio, Inc.

Market Cap

$280M

Live price × SEC shares (Oct 30, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

3.53

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

1.0

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Research & development	36,194	37,353	44,430	47,144	165,121
Total operating expenses	42,611	44,296	52,021	54,707	193,635
Operating income	(42,611)	(44,296)	(52,021)	(54,707)	(193,635)
Interest expense	555	636	517	511	2,219
Income tax	0.00	0.00	0.00	0.00	0.00
Net income	(41,919)	(43,515)	(51,018)	(53,053)	(189,505)
EPS (basic) ($)		(0.39)	(0.34)	(0.28)	(1.33)
EPS (diluted) ($)		(0.39)	(0.34)	(0.28)	(1.33)
Weighted avg. shares (basic)		112,025	151,160	186,784
Weighted avg. shares (diluted)		112,025	151,160	186,784

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 5, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 29 more quarters, back to Sep 2018, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

T. Rowe Price amends its reported ownership in Cabaletta Bio (CABA).

Stock Titan · 2026-11-06

Cabaletta Bio, Inc. (CABA) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-11-06

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Yahoo · 2026-11-05

Cabaletta Bio Q3 EPS $(0.28) Beats $(0.33) Estimate

Benzinga · 2026-11-05

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo · 2026-11-04

Cabaletta Bio to Participate in Upcoming Investor Conferences

Yahoo · 2026-11-03

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

SeekingAlpha · 2026-10-13

CABA Stock Slips As Traders Weigh Cash Runway And Losses

Timothy Sykes · 2026-10-13

CABA Stock Slides As Traders Weigh Cash Runway And Losses

StocksToTrade · 2026-10-13

CABA Forecast — Price Target — Prediction for 2027

TradingView · 2026-06-25

How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup

Yahoo Finance · 2026-06-17

Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases

Yahoo Finance · 2026-06-07

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Yahoo Finance · 2026-06-03

Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis

Yahoo Finance · 2026-05-21

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?

Yahoo Finance · 2026-05-20

Informational purposes only, not investment advice.